M Angela Cenci Nilsson

List of Publications by Citations

107 papers	8,277 citations	47 h-index	90 g-index
113 ext. papers	9,148 ext. citations	6.6 avg, IF	6.18 L-index

#	Paper	IF	Citations
107	Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. *Nature Neuroscience*, **2003**, 6, 501-6	25.5	692
106	Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. *European Journal of Neuroscience*, **2002**, 15, 120-32	3.5	515
105	Animal models of neurological deficits: how relevant is the rat?. *Nature Reviews Neuroscience*, **2002**, 3, 574-9	13.5	378
104	L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. *Neurobiology of Disease*, **2002**, 10, 165-86	7.5	338
103	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. *Progress in Neurobiology*, **2015**, 132, 96-168	10.9	282
102	Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. *Biological Psychiatry*, **2007**, 62, 800-10	7.9	228
101	Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. *Trends in Neurosciences*, **2007**, 30, 236-43	13.3	216
100	L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. *Journal of Neurochemistry*, **2010**, 112, 1465-76	6	206
99	Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. *Annals of Neurology*, **2010**, 68, 619-28	9.4	192
98	Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. *Behavioural Brain Research*, **2007**, 179, 76-89	3.4	184
97	Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. *Journal of Neurochemistry*, **2007**, 101, 483-97	6	183
96	Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. *Brain Research*, **1992**, 581, 217-28	3.7	182
95	Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. *Nature Communications*, **2014**, 5, 5316	17.4	181
94	Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. *Journal of Neurochemistry*, **2006**, 99, 381-92	6	176
93	Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. *Progress in Brain Research*, **2010**, 183, 209-33	2.9	163
92	Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. *Current Protocols in Neuroscience*, **2007**, Chapter 9, Unit 9.25	2.7	162
91	Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 330, 227-35	4.7	146

90	Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. *Brain*, **2014**, 137, 1998-2014	11.2	139
89	Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. *Progress in Neurobiology*, **2012**, 96, 69-86	10.9	137
88	Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. *Frontiers in Neurology*, **2014**, 5, 242	4.1	136
87	A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. *Neurobiology of Disease*, **2010**, 39, 352-61	7.5	135
86	Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. *Neurobiology of Disease*, **2004**, 17, 219-36	7.5	131
85	M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. *Neuron*, **2015**, 88, 762-73	13.9	129
84	Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 21824-9	11.5	126
83	Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. *Neurobiology of Disease*, **2011**, 42, 327-40	7.5	121
82	Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. *Journal of Neuroscience*, **2004**, 24, 5283-91	6.6	121
81	cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. *Journal of Neuroscience*, **2001**, 21, 9930-43	6.6	120
80	Striatal c-fos Induction by Cocaine or Apomorphine Occurs Preferentially in Output Neurons Projecting to the Substantia Nigra in the Rat. *European Journal of Neuroscience*, **1992**, 4, 376-380	3.5	117
79	Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. *Brain Research Bulletin*, **2006**, 69, 318-26	3.9	114
78	Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. *Journal of Neuroscience*, **2006**, 26, 9448-61	6.6	105
77	Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. *Brain*, **2011**, 134, 2339-57	11.2	96
76	l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. *Neurobiology of Disease*, **2008**, 29, 327-35	7.5	89
75	Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. *Neurobiology of Disease*, **2006**, 21, 657-68	7.5	88
74	Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. *Journal of Neuroscience*, **2012**, 32, 16541-51	6.6	87
73	Advances in understanding L-DOPA-induced dyskinesia. *Current Opinion in Neurobiology*, **2007**, 17, 665-71	7.6	86

72	The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. *Behavioural Brain Research*, **2007**, 177, 150-9	3.4	86
71	Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 4578-83	11.5	81
70	Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. *Journal of Neurochemistry*, **2010**, 114, 499-511	6	77
69	Increased CSF biomarkers of angiogenesis in Parkinson disease. *Neurology*, **2015**, 85, 1834-42	6.5	75
68	Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. *Journal of Clinical Investigation*, **2017**, 127, 720-734	15.9	75
67	Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. *Neuropsychopharmacology*, **2009**, 34, 2477-88	8.7	70
66	Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. *Biological Psychiatry*, **2009**, 65, 518-26	7.9	66
65	Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. *Journal of Neuroscience*, **2014**, 34, 4728-40	6.6	65
64	Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. *Brain Research Bulletin*, **2005**, 68, 4-15	3.9	63
63	In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. *Neurobiology of Disease*, **2012**, 45, 573-82	7.5	59
62	Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. *NeuroImage*, **2012**, 61, 228-39	7.9	57
61	Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia. *Neuropharmacology*, **2015**, 93, 52-67	5.5	55
60	Animal models of l-dopa-induced dyskinesia in Parkinson's disease. *Movement Disorders*, **2018**, 33, 889-899	7	47
59	Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease. *Experimental Neurology*, **2017**, 298, 137-147	5.7	40
58	The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study. *PLoS ONE*, **2011**, 6, e24679	3.7	40
57	Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 3, S59-63	3.6	40
56	L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. *Parkinsonism and Related Disorders*, **2007**, 13 Suppl 3, S263-7	3.6	39
55	Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. *Neuropharmacology*, **2015**, 95, 121-9	5.5	38

54	Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia. *Movement Disorders*, **2015**, 30, 484-93	7	38
53	Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. *Experimental Neurology*, **2013**, 250, 116-24	5.7	37
52	mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia. *Current Opinion in Pharmacology*, **2018**, 38, 81-89	5.1	36
51	Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. *Neurobiology of Disease*, **2016**, 96, 156-170	7.5	36
50	Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. *Journal of Neurochemistry*, **2007**, 102, 1395-409	6	35
49	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. *Acta Neuropathologica Communications*, **2018**, 6, 2	7.3	34
48	Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. *Neurotherapeutics*, **2019**, 16, 465-479	6.4	34
47	Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. *Neurobiology of Disease*, **2009**, 35, 42-51	7.5	31
46	Chronic intermittent L-DOPA treatment induces changes in dopamine release. *Journal of Neurochemistry*, **2009**, 108, 998-1008	6	30
45	On the neuronal circuitry mediating L-DOPA-induced dyskinesia. *Journal of Neural Transmission*, **2018**, 125, 1157-1169	4.3	26
44	Rodent models of treatment-induced motor complications in Parkinson's disease. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 4, S13-7	3.6	24
43	Dyskinesia matters. *Movement Disorders*, **2020**, 35, 392-396	7	24
42	Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse. *Parkinsonism and Related Disorders*, **2014**, 20 Suppl 1, S20-2	3.6	20
41	Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease. *Neurobiology of Disease*, **2017**, 105, 117-131	7.5	19
40	Seeding of protein aggregation causes cognitive impairment in rat model of cortical synucleinopathy. *Movement Disorders*, **2019**, 34, 1699-1710	7	18
39	Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4375-84	11.5	18
38	Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached?. *Neurobiology of Disease*, **2015**, 82, 561-573	7.5	17
37	Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion. *Neurobiology of Disease*, **2016**, 94, 213-25	7.5	17

36	Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. *Experimental Neurology*, **2010**, 225, 408-15	5.7	17
35	D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease. *Journal of Clinical Investigation*, **2020**, 130, 1168-1184	15.9	17
34	Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. *Scientific Reports*, **2017**, 7, 16005	4.9	15
33	Host Brain Regulation of Fetal Locus Coeruleus Neurons Grafted to the Hippocampus in 6-Hydroxydopamine-Treated Rats. An Intracerebral Microdialysis Study. *European Journal of Neuroscience*, **1991**, 3, 905-918	3.5	14
32	A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine. *Molecular Neurobiology*, **2015**, 52, 1152-1164	6.2	13
31	Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 1423-8	11.5	13
30	Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease. *Biochemical Society Transactions*, **2014**, 42, 600-4	5.1	12
29	Utility of 6-Hydroxydopamine Lesioned Rats in the Preclinical Screening of Novel Treatments for Parkinson Disease **2005**, 193-208		12
28	The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications. *Progress in Brain Research*, **2020**, 252, 131-168	2.9	10
27	Animal models for preclinical Parkinson's research: An update and critical appraisal. *Progress in Brain Research*, **2020**, 252, 27-59	2.9	10
26	Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model. *Neurobiology of Disease*, **2016**, 96, 31-37	7.5	10
25	A model of GDNF gene therapy in mice with 6-Hydroxydopamine lesions: time course of Neurorestorative effects and ERK1/2 activation. *Journal of Parkinsonʼs Disease*, **2012**, 2, 333-48	5.3	10
24	CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors. *Journal of Neuroscience*, **2017**, 37, 11930-11946	6.6	9
23	Significance and Translational Value of High-Frequency Cortico-Basal Ganglia Oscillations in Parkinson's Disease. *Journal of Parkinsonʼs Disease*, **2019**, 9, 183-196	5.3	7
22	Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease. *Experimental Neurology*, **2017**, 292, 113-124	5.7	5
21	Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.. *Neuropharmacology*, **2022**, 210, 109027	5.5	4
20	Etiology and Pathogenesis of Parkinson Disease **2017**, 95-101		3
19	Cortico-Striatal Oscillations Are Correlated to Motor Activity Levels in Both Physiological and Parkinsonian Conditions. *Frontiers in Systems Neuroscience*, **2020**, 14, 56	3.5	3

18	Recent advances in Parkinson's disease: basic research. Preface. *Progress in Brain Research*, **2010**, 183, ix-x	2.9	2
17	Recent Advances in Parkinson's disease - translational and clinical research. *Progress in Brain Research*, **2010**, 184, vii-viii	2.9	2
16	On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease. *Experimental Neurology*, **2006**, 201, 1-6	5.7	2
15	On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats. *Movement Disorders*, **2016**, 31, 149	7	2
14	Bad news for neuroprotective therapies in PD?. *Journal of Parkinson's Disease*, **2013**, 3, 271-3	5.3	1
13	Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism. *Neurobiology of Disease*, **2021**, 157, 105429	7.5	1
12	Non-Apoptotic Caspase-3 Activation Mediates Early Synaptic Dysfunction of Indirect Pathway Neurons in the Parkinsonian Striatum. *International Journal of Molecular Sciences*, **2022**, 23, 5470	6.3	0
11	Rodent Models of Treatment-Related Complications in Parkinson Disease **2015**, 373-386		
10	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. *Movement Disorders*, **2020**, 35, 901	7	
9	Signaling Mechanisms in l-DOPA-Induced Dyskinesia. *Innovations in Cognitive Neuroscience*, **2016**, 155-185		
8	6-OH Dopamine Rat Model **2010**, 3-5		
7	Molecular Mechanisms of l-DOPA-Induced Dyskinesia. *Handbook of Behavioral Neuroscience*, **2010**, 625-640	7	
6	Models for human neurological disease: both rats and primates are needed. *Nature Reviews Neuroscience*, **2002**, 3, 580-580	13.5	
5	Toxin-Based Rodent Models of Parkinson's Disease. *Neuromethods*, **2021**, 3-19	0.4	
4	Tail-pinch Stimulus **2010**, 209-210		
3	Climbing Behavior **2010**, 226-227		
2	Preclinical Models of Levodopa-Induced Dyskinesia **2014**, 335-353		
1	Posters presentation selected for the blue ribbon session at the annual meeting of the Parkinson's disease and movement disorders society (Hong Kong, October, 2018).. *Movement Disorders*, **2018**, 33, 1977-1991	7	